Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00)
• Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24)
• Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34)
• Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative, CLDN18.2-negative metastatic gastric cancer — Dr Mulherin (28:15)
• Case: A woman in her early 70s with metastatic gastroesophageal junction adenocarcinoma (PD-L1 CPS 15) who begins treatment with FOLFOX/nivolumab and subsequently is found to have CLDN18.2 overexpression — Dr Lamar (35:23)
• Case: A man in his mid 40s with CLDN18.2-positive metastatic esophageal adenocarcinoma (PD-L1 10%) who receives mFOLFOX6 and zolbetuximab — Dr Yannucci (42:54)

CE information and select publications

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00)
• Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15)
• Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline mutation — Dr Yannucci (26:27)
• Case: A woman in her mid 60s with OC and a BRCA2 somatic mutation who develops cytopenias on maintenance olaparib — Dr Lamar (35:47)
• Case: A woman in her early 70s with HER2 IHC 2+, ER-expressing, FOLR1-positive OC — Dr Warsch (42:54)

CE information and select publications

Featuring perspectives from Dr Kerry Rogers, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Chronic Lymphocytic Leukemia (CLL) — Dr Rogers (0:00)
• Case: A man in his mid 70s with CLL and a history of atrial fibrillation — Dr Lamar (13:08)
• Case: A fit man in his early 80s with IGHV-unmutated, TP53-mutant symptomatic CLL — Dr Mulherin (21:16)
• Case: A woman in her mid 80s with IGHV-mutated recurrent CLL who receives pirtobrutinib — Dr Warsch (32:41)
• Case: A woman in her late 70s with recurrent del(17p) CLL who receives venetoclax/obinutuzumab — Dr Yannucci (44:52)

CE information and select publications